BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 36839249)

  • 1. Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease.
    Iwaki M; Kobayashi T; Nogami A; Saito S; Nakajima A; Yoneda M
    Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Li G; Rios RS; Wang XX; Yu Y; Zheng KI; Huang OY; Tang LJ; Ma HL; Jin Y; Targher G; Byrne CD; Pan XY; Zheng MH
    Br J Nutr; 2022 Jun; 127(11):1613-1620. PubMed ID: 34176541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis.
    Chakravarthy MV; Siddiqui MS; Forsgren MF; Sanyal AJ
    Front Endocrinol (Lausanne); 2020; 11():592373. PubMed ID: 33424768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appendicular Skeletal Muscle Mass to Visceral Fat Area Ratio Predicts Hepatic Morbidities.
    Han E; Lee YH; Ahn SH; Cha BS; Kim SU; Lee BW
    Gut Liver; 2024 May; 18(3):509-519. PubMed ID: 38013477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review.
    Armandi A; Rosso C; Caviglia GP; Ribaldone DG; Bugianesi E
    Front Endocrinol (Lausanne); 2021; 12():716533. PubMed ID: 34858322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.
    Petta S; Ciminnisi S; Di Marco V; Cabibi D; Cammà C; Licata A; Marchesini G; Craxì A
    Aliment Pharmacol Ther; 2017 Feb; 45(4):510-518. PubMed ID: 28028821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis.
    Song W; Yoo SH; Jang J; Baik SJ; Lee BK; Lee HW; Park JS
    Gut Liver; 2023 Jan; 17(1):130-138. PubMed ID: 36472070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease.
    Shida T; Akiyama K; Oh S; Sawai A; Isobe T; Okamoto Y; Ishige K; Mizokami Y; Yamagata K; Onizawa K; Tanaka H; Iijima H; Shoda J
    J Gastroenterol; 2018 Apr; 53(4):535-547. PubMed ID: 28791501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lean nonalcoholic fatty liver disease and sarcopenia.
    Chen M; Cao Y; Ji G; Zhang L
    Front Endocrinol (Lausanne); 2023; 14():1217249. PubMed ID: 37424859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease.
    Zambon Azevedo V; Silaghi CA; Maurel T; Silaghi H; Ratziu V; Pais R
    Front Nutr; 2021; 8():774030. PubMed ID: 35111794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice.
    El Sherif O; Dhaliwal A; Newsome PN; Armstrong MJ
    Expert Rev Gastroenterol Hepatol; 2020 Mar; 14(3):197-205. PubMed ID: 32064966
    [No Abstract]   [Full Text] [Related]  

  • 13. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models.
    Nachit M; De Rudder M; Thissen JP; Schakman O; Bouzin C; Horsmans Y; Vande Velde G; Leclercq IA
    J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):144-158. PubMed ID: 33244884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1.
    Cabrera D; Ruiz A; Cabello-Verrugio C; Brandan E; Estrada L; Pizarro M; Solis N; Torres J; Barrera F; Arrese M
    Dig Dis Sci; 2016 Nov; 61(11):3190-3198. PubMed ID: 27572941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease in the over-60s: Impact of sarcopenia and obesity.
    Wijarnpreecha K; Panjawatanan P; Aby E; Ahmed A; Kim D
    Maturitas; 2019 Jun; 124():48-54. PubMed ID: 31097179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A significant association of non-obese non-alcoholic fatty liver disease with sarcopenic obesity.
    Kashiwagi K; Takayama M; Fukuhara K; Shimizu-Hirota R; Chu PS; Nakamoto N; Inoue N; Iwao Y; Kanai T
    Clin Nutr ESPEN; 2020 Aug; 38():86-93. PubMed ID: 32690183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenic obesity in fatty liver.
    Merli M; Lattanzi B; Aprile F
    Curr Opin Clin Nutr Metab Care; 2019 May; 22(3):185-190. PubMed ID: 30893090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcopenia and fatty liver disease.
    Kim JA; Choi KM
    Hepatol Int; 2019 Nov; 13(6):674-687. PubMed ID: 31705444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution.
    Alferink LJM; Trajanoska K; Erler NS; Schoufour JD; de Knegt RJ; Ikram MA; Janssen HLA; Franco OH; Metselaar HJ; Rivadeneira F; Darwish Murad S
    J Bone Miner Res; 2019 Jul; 34(7):1254-1263. PubMed ID: 31074909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011).
    Lee YH; Kim SU; Song K; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Han KH
    Hepatology; 2016 Mar; 63(3):776-86. PubMed ID: 26638128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.